Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.86
NAS:BABY's Cash-to-Debt is ranked lower than
69% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. NAS:BABY: 0.86 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BABY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 44.72 Max: No Debt
Current: 0.86
Equity-to-Asset 0.60
NAS:BABY's Equity-to-Asset is ranked higher than
51% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NAS:BABY: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BABY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.79  Med: 0.82 Max: 0.94
Current: 0.6
-1.79
0.94
Debt-to-Equity 0.36
NAS:BABY's Debt-to-Equity is ranked higher than
52% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. NAS:BABY: 0.36 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:BABY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.1  Med: 0.02 Max: 0.36
Current: 0.36
-0.1
0.36
Debt-to-EBITDA 3.38
NAS:BABY's Debt-to-EBITDA is ranked lower than
57% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. NAS:BABY: 3.38 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:BABY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03  Med: 1.28 Max: 16.94
Current: 3.38
0.03
16.94
Interest Coverage 5.48
NAS:BABY's Interest Coverage is ranked lower than
73% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. NAS:BABY: 5.48 )
Ranked among companies with meaningful Interest Coverage only.
NAS:BABY' s Interest Coverage Range Over the Past 10 Years
Min: 5.48  Med: 100.22 Max: 151.91
Current: 5.48
5.48
151.91
Piotroski F-Score: 5
Altman Z-Score: 4.13
Beneish M-Score: -2.57
WACC vs ROIC
8.27%
-0.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 3.89
NAS:BABY's Operating Margin % is ranked higher than
59% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. NAS:BABY: 3.89 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BABY' s Operating Margin % Range Over the Past 10 Years
Min: -4.44  Med: 11.48 Max: 15.75
Current: 3.89
-4.44
15.75
Net Margin % -0.62
NAS:BABY's Net Margin % is ranked higher than
60% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. NAS:BABY: -0.62 )
Ranked among companies with meaningful Net Margin % only.
NAS:BABY' s Net Margin % Range Over the Past 10 Years
Min: -4.8  Med: 7.55 Max: 11.15
Current: -0.62
-4.8
11.15
ROE % -0.71
NAS:BABY's ROE % is ranked higher than
58% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. NAS:BABY: -0.71 )
Ranked among companies with meaningful ROE % only.
NAS:BABY' s ROE % Range Over the Past 10 Years
Min: -4.28  Med: 8.52 Max: 10.54
Current: -0.71
-4.28
10.54
ROA % -0.46
NAS:BABY's ROA % is ranked higher than
63% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. NAS:BABY: -0.46 )
Ranked among companies with meaningful ROA % only.
NAS:BABY' s ROA % Range Over the Past 10 Years
Min: -3.46  Med: 5.94 Max: 8.3
Current: -0.46
-3.46
8.3
ROC (Joel Greenblatt) % 16.91
NAS:BABY's ROC (Joel Greenblatt) % is ranked higher than
70% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. NAS:BABY: 16.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BABY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.53  Med: 41.37 Max: 56.94
Current: 16.91
-12.53
56.94
3-Year Revenue Growth Rate 1.10
NAS:BABY's 3-Year Revenue Growth Rate is ranked lower than
61% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. NAS:BABY: 1.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BABY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.9  Med: 10.65 Max: 38.3
Current: 1.1
-61.9
38.3
3-Year EBITDA Growth Rate 13.20
NAS:BABY's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NAS:BABY: 13.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BABY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -88.5  Med: 22.8 Max: 863.2
Current: 13.2
-88.5
863.2
3-Year EPS without NRI Growth Rate 19.80
NAS:BABY's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NAS:BABY: 19.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BABY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: -1.6 Max: 106.2
Current: 19.8
-52.8
106.2
GuruFocus has detected 1 Warning Sign with Natus Medical Inc NAS:BABY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BABY's 30-Y Financials

Financials (Next Earnings Date: 2018-02-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BABY Guru Trades in Q4 2016

Steven Cohen 74,900 sh (New)
Paul Tudor Jones 16,520 sh (New)
Jim Simons 45,800 sh (+246.97%)
Columbia Wanger 590,825 sh (+122.95%)
Robert Olstein 77,795 sh (+39.29%)
Joel Greenblatt 147,129 sh (+3.10%)
Diamond Hill Capital 589,551 sh (-0.03%)
Ken Fisher 610,049 sh (-0.29%)
» More
Q1 2017

BABY Guru Trades in Q1 2017

Mariko Gordon 1,300,949 sh (New)
Columbia Wanger 2,030,207 sh (+243.62%)
Jim Simons 149,294 sh (+225.97%)
Robert Olstein 86,845 sh (+11.63%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 597,674 sh (-2.03%)
Diamond Hill Capital 575,594 sh (-2.37%)
Joel Greenblatt 112,248 sh (-23.71%)
» More
Q2 2017

BABY Guru Trades in Q2 2017

Steven Cohen 256,500 sh (New)
Mariko Gordon 1,470,839 sh (+13.06%)
Robert Olstein 86,845 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 588,299 sh (-1.57%)
Diamond Hill Capital 545,149 sh (-5.29%)
Jim Simons 126,962 sh (-14.96%)
Columbia Wanger 1,697,388 sh (-16.39%)
» More
Q3 2017

BABY Guru Trades in Q3 2017

Chuck Royce 251 sh (New)
Ken Fisher 589,234 sh (+0.16%)
Jim Simons Sold Out
Steven Cohen Sold Out
Robert Olstein 86,200 sh (-0.74%)
Diamond Hill Capital 528,624 sh (-3.03%)
Mariko Gordon 1,385,533 sh (-5.80%)
Columbia Wanger 1,171,097 sh (-31.01%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2017-09-30 Reduce -5.80%0.19%$32 - $39.1 $ 39.5512%1,385,533
Ken Fisher 2017-09-30 Add 0.16%$32 - $39.1 $ 39.5512%589,234
Robert Olstein 2017-09-30 Reduce -0.74%$32 - $39.1 $ 39.5512%86,200
Mariko Gordon 2017-06-30 Add 13.06%0.38%$33.6 - $40.9 $ 39.559%1,470,839
Ken Fisher 2017-06-30 Reduce -1.57%$33.6 - $40.9 $ 39.559%588,299
Joel Greenblatt 2017-06-30 Sold Out 0.06%$33.6 - $40.9 $ 39.559%0
Mariko Gordon 2017-03-31 New Buy2.98%$35.1 - $39.5 $ 39.555%1,300,949
Ken Fisher 2017-03-31 Reduce -2.03%$35.1 - $39.5 $ 39.555%597,674
Joel Greenblatt 2017-03-31 Reduce -23.71%0.02%$35.1 - $39.5 $ 39.555%112,248
Robert Olstein 2017-03-31 Add 11.63%0.05%$35.1 - $39.5 $ 39.555%86,845
Ken Fisher 2016-12-31 Reduce -0.29%$33.6 - $43.7 $ 39.551%610,049
Joel Greenblatt 2016-12-31 Add 3.10%$33.6 - $43.7 $ 39.551%147,129
Robert Olstein 2016-12-31 Add 39.29%0.1%$33.6 - $43.7 $ 39.551%77,795
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:MDXG, SZSE:300298, SHSE:603387, TSE:7817, SHSE:603579, TSE:6960, XTER:DRW3, XPAR:GBT, SZSE:300273, SZSE:300642, SZSE:000607, OTCPK:NMRD, SZSE:002317, NAS:CNMD, SHSE:600587, NAS:OFIX, HKSE:01302, SZSE:300633, XTER:SBS, SZSE:300216 » details
Traded in other countries:NM4.Germany,
Headquarter Location:USA
Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders.

Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders.

Ratios

vs
industry
vs
history
Forward PE Ratio 19.16
BABY's Forward PE Ratio is ranked higher than
80% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. BABY: 19.16 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.08
BABY's PB Ratio is ranked higher than
51% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. BABY: 3.08 )
Ranked among companies with meaningful PB Ratio only.
BABY' s PB Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.46 Max: 4.26
Current: 3.08
0.79
4.26
PS Ratio 2.72
BABY's PS Ratio is ranked higher than
54% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. BABY: 2.72 )
Ranked among companies with meaningful PS Ratio only.
BABY' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.51 Max: 4.42
Current: 2.72
0.95
4.42
Price-to-Free-Cash-Flow 88.11
BABY's Price-to-Free-Cash-Flow is ranked higher than
54% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. BABY: 88.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BABY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.63  Med: 29.4 Max: 521.25
Current: 88.11
12.63
521.25
Price-to-Operating-Cash-Flow 69.96
BABY's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. BABY: 69.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BABY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.19  Med: 24.61 Max: 108.31
Current: 69.96
10.19
108.31
EV-to-EBIT 60.49
BABY's EV-to-EBIT is ranked lower than
83% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. BABY: 60.49 )
Ranked among companies with meaningful EV-to-EBIT only.
BABY' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.6  Med: 23.2 Max: 97.2
Current: 60.49
-29.6
97.2
EV-to-EBITDA 27.51
BABY's EV-to-EBITDA is ranked lower than
69% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. BABY: 27.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
BABY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.2  Med: 17 Max: 5653.1
Current: 27.51
-82.2
5653.1
EV-to-Revenue 2.62
BABY's EV-to-Revenue is ranked higher than
56% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. BABY: 2.62 )
Ranked among companies with meaningful EV-to-Revenue only.
BABY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 2.4 Max: 4.4
Current: 2.62
0.8
4.4
Shiller PE Ratio 72.03
BABY's Shiller PE Ratio is ranked lower than
65% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. BABY: 72.03 )
Ranked among companies with meaningful Shiller PE Ratio only.
BABY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 43.71  Med: 77.81 Max: 115
Current: 72.03
43.71
115
Current Ratio 4.21
BABY's Current Ratio is ranked higher than
64% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. BABY: 4.21 )
Ranked among companies with meaningful Current Ratio only.
BABY' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 3.28 Max: 16.01
Current: 4.21
1.3
16.01
Quick Ratio 3.36
BABY's Quick Ratio is ranked higher than
60% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. BABY: 3.36 )
Ranked among companies with meaningful Quick Ratio only.
BABY' s Quick Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.57 Max: 15.09
Current: 3.36
0.91
15.09
Days Inventory 109.51
BABY's Days Inventory is ranked higher than
65% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. BABY: 109.51 )
Ranked among companies with meaningful Days Inventory only.
BABY' s Days Inventory Range Over the Past 10 Years
Min: 104.01  Med: 123.48 Max: 132.84
Current: 109.51
104.01
132.84
Days Sales Outstanding 89.23
BABY's Days Sales Outstanding is ranked lower than
72% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. BABY: 89.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
BABY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.74  Med: 86.98 Max: 112.34
Current: 89.23
81.74
112.34
Days Payable 31.98
BABY's Days Payable is ranked lower than
57% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. BABY: 31.98 )
Ranked among companies with meaningful Days Payable only.
BABY' s Days Payable Range Over the Past 10 Years
Min: 31.98  Med: 67.82 Max: 92.09
Current: 31.98
31.98
92.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
BABY's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. BABY: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BABY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -185.4  Med: -3.4 Max: -1.6
Current: -1.6
-185.4
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 21.26
BABY's Price-to-Net-Current-Asset-Value is ranked lower than
84% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. BABY: 21.26 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BABY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.09  Med: 6.63 Max: 2050
Current: 21.26
1.09
2050
Price-to-Tangible-Book 12.68
BABY's Price-to-Tangible-Book is ranked lower than
81% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. BABY: 12.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BABY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.02  Med: 5.17 Max: 64.5
Current: 12.68
1.02
64.5
Price-to-Intrinsic-Value-Projected-FCF 1.90
BABY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
65% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. BABY: 1.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BABY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.79  Med: 1.7 Max: 5.27
Current: 1.9
0.79
5.27
Price-to-Median-PS-Value 1.08
BABY's Price-to-Median-PS-Value is ranked lower than
55% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. BABY: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BABY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.02 Max: 2.91
Current: 1.08
0.12
2.91
Price-to-Peter-Lynch-Fair-Value 8.89
BABY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. BABY: 8.89 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BABY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.5 Max: 8.98
Current: 8.89
0
8.98
Earnings Yield (Greenblatt) % 1.63
BABY's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. BABY: 1.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BABY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6.2  Med: 4 Max: 19.5
Current: 1.63
-6.2
19.5
Forward Rate of Return (Yacktman) % 12.80
BABY's Forward Rate of Return (Yacktman) % is ranked higher than
63% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. BABY: 12.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BABY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.5  Med: 3.3 Max: 75
Current: 12.8
-0.5
75

More Statistics

Revenue (TTM) (Mil) $477.23
EPS (TTM) $ -0.09
Beta1.05
Short Percentage of Float12.33%
52-Week Range $31.65 - 43.60
Shares Outstanding (Mil)31.15

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 515 563 591 625
EPS ($) 1.75 2.04 2.16 2.41
EPS without NRI ($) 1.75 2.04 2.16 2.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}